Article Archive

Page 10 of 99 · 4749 patient-friendly summaries

Myofibroblast Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and its Inhibition Exerts Anti-Fibrotic Properties.
Gastroenterology

Myofibroblast Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and its Inhibition Exerts Anti-Fibrotic Properties.

TG2 produced by intestinal myofibroblasts may drive fibrosis and strictures in Crohn's disease independently of inflammation; blocking TG2 reduced fibrosis in lab and mouse models, pointing to a possible new...

Read Summary
Early-life animal exposure was not associated with risk of inflammatory bowel disease: a nationwide birth cohort study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Early-life animal exposure was not associated with risk of inflammatory bowel disease: a nationwide birth cohort study.

This large, long-term study suggests that having pets or farm animals during pregnancy or early childhood probably does not meaningfully change a child’s later risk of developing IBD, which may reassure families...

Read Summary
Statistical caution before adopting a data-driven day-3 PUCAI cut-off in flare-onset paediatric acute severe ulcerative colitis.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Statistical caution before adopting a data-driven day-3 PUCAI cut-off in flare-onset paediatric acute severe ulcerative colitis.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Digestive and liver...

Read Summary

Prediction of incident inflammatory bowel disease from routine electronic health records: development and external validation of a longitudinal machine learning model

Earlier identification of people likely to develop IBD could shorten diagnostic delays that are linked to worse outcomes, and an automated EHR model might help target who should get earlier evaluation.

Read Summary
Long-term comparative effectiveness of first-line infliximab vs corticosteroids in ulcerative colitis: Remission and colectomy risk
World Journal of Gastroenterology

Long-term comparative effectiveness of first-line infliximab vs corticosteroids in ulcerative colitis: Remission and colectomy risk

The study suggests that using infliximab as first-line therapy (rather than IV corticosteroids) may produce more durable remission and reduce long-term colectomy risk in moderate-to-severe ulcerative colitis.

Read Summary
Agomab doses first patient in ~320-patient Crohn's trial | AGMB Stock News - Stock Titan
stocktitan.net

Agomab doses first patient in ~320-patient Crohn's trial | AGMB Stock News - Stock Titan

This advances a drug candidate (ontunisertib) aimed specifically at fibrostenosing Crohn’s disease — a form of IBD where strictures can block the bowel and endoscopic passability is a meaningful clinical measure.

Read Summary